More IPO paperwork filed: Natera to test out the public market with $100 million IPO
Just two months after raising $55.5 million in a private financing round, Natera (San Carlos, California) filed IPO paperwork with the SEC that could bring in as much as $100 million in an initial public offering. Natera makes DNA-based genetic tests. The company has developed its technology for prenatal testing and is also developing blood-based diagnostics for cancer.
The morcellator non-story
We've all heard about the FBI investigation into manufacturers of power morcellators, and much of the coverage comes across as breathlessness in search of a scandal. This story goes back to at least 2006 when Ethicon, the Johnson & Johnson subsidiary that withdrew its morcellators from the market last year, appended product labels to advise physicians of the potential for the spread of uterine neoplasms during morcellation for hysterectomy or fibroid removal.
EuroPCR 2015: Safer, efficient TAVI challenges surgery as gold standard
PARIS Citing clinical results they qualified as "fabulous," and "impressive," two key opinion leaders affiliated with Edwards Lifesciences (Irvine, California) are calling for an end to the dominance of open-chest surgery as the gold standard for treating patients with stenosis of the aortic valve.